United States — Food and Drug Administration & Novo Nordisk
11 shared events · Importance 4 · Last updated Apr 20, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United States — Food and Drug Administration: The FDA has been cracking down on compounded GLP-1s; the study supports the need for further regulatory action.
Novo Nordisk: Novo Nordisk's Wegovy is one of the GLP-1 drugs being prescribed via telehealth; the study may lead to stricter oversight that could affect sales.
Jul 07, 2026 · 6 articles
Domestic
United States — Food and Drug Administration: The FDA approved semaglutide for diabetes and weight management but not for alcohol use disorder; the trial may lead to a new indication.
Novo Nordisk: Novo Nordisk's semaglutide is the drug being tested; positive results could expand its approved uses and market, though the trial is early-stage.
Jul 30, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA granted priority review to Agios' sNDA, setting a November 1 PDUFA date; its decision will determine mitapivat's market access.
Novo Nordisk: Novo Nordisk is a competitor developing a rival oral PK activator; its positive trial data adds competitive pressure on Agios.
Jul 07, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
Tech
Novo Nordisk: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard